However, as illustrated in Fig. 3, KRAS mutations are also noteworthy in a variety of other cancer types including small intestine adenocarcinoma (26%), biliary tract cancers [cholangiocarcinoma (23%), gallbladder carcinoma (16%)], plasma cell myeloma (18%), and anaplastic thyroid carcinoma (8.6%). Here, KRAS is linked to cholangiocarcinoma.